89687
document
Leukotriene antagonist prevents exacerbation of asthma during reduction of high-dose inhaled corticosteroid . The Tokyo Joshi-Idai Asthma Research Group . To test whether the leukotriene antagonist ONO-1078 ( pranlukast ) prevents asthma exacerbations during reduction of high-dose inhaled corticosteroid , we conducted a randomized , double-blind , placebo-controlled study in 79 asthma patients requiring high doses ( 1,500 microg/d or more ) of inhaled beclomethasone dipropionate ( BDI ) for clinical control ( duration of asthma , 11.0 +/- 3.1 yr ; duration of BDI treatment , 0.5 +/- 0.3 yr ; FEV1 percentage of predicted , 80.7 +/- 2.0 % ) . After a 2-wk run-in period , the doses of BDI were halved , while the patients were assigned to receive orally ONO-1078 , 450 mg twice daily , or placebo . In the placebo group FEV1 decreased by 0.33 +/- 0.20 L after 6 wk ( p < 0.001 ) . Likewise , morning and evening PEF decreased by 46 +/- 7 L/min and 18 +/- 6 L/min , respectively . By contrast these variables were sustained above baseline in the ONO-1078 group . The number of daytime and nighttime asthma symptoms and the use of beta2-agonist increased in the placebo group , whereas they remained unchanged in the ONO-1078 group . In the placebo group concentrations of serum eosinophil cationic protein and exhaled nitric oxide increased ( p = 0.007 and p = 0.025 , respectively ) , compared with no change in the ONO-1078 group . Therefore , the leukotriene antagonist ONO-1078 prevents the asthma deterioration provoked by a 6-wk reduction of the dose of inhaled BDI into half .
89688
Intervention_Pharmacological
Leukotriene antagonist
89689
Intervention_Pharmacological
leukotriene antagonist ONO-1078 ( pranlukast )
89690
Intervention_Pharmacological
corticosteroid
89691
Intervention_Pharmacological
inhaled beclomethasone dipropionate ( BDI )
89692
Intervention_Pharmacological
orally ONO-1078 , 450 mg twice daily
89693
Intervention_Control
placebo
89694
Intervention_Control
placebo
89695
Intervention_Control
placebo
89696
Intervention_Pharmacological
leukotriene antagonist ONO-1078
89697
Outcome_Physical
FEV1
89698
Outcome_Physical
morning and evening PEF
89699
Outcome_Physical
number of daytime and nighttime asthma symptoms
89700
Outcome_Physical
use of beta2-agonist
89701
Outcome_Physical
concentrations of serum eosinophil cationic protein and exhaled nitric oxide
89702
Participant_Condition
asthma
89703
Participant_Condition
asthma
89704
Participant_Condition
asthma patients
89705
Participant_Condition
inhaled beclomethasone dipropionate
89706
Participant_Condition
asthma